Archive summary Clinical & research

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 ...

BPL‐003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studiesCommercial readiness advancing with scalable treatment model

Summary of reporting by hastingstribune March 10, 2026 1 min read Markdown